NCT07310264
Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 5 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Sep 28, 2026 to Nov 10, 2026
- Enrollment target: estimated 84 to confirmed 80
- Secondary endpoints: details revised at 4 of 14 entries
- Site details revised
- Notable Eligibility criteria expanded, about 12 words
- Secondary endpoints: 15 to 14
- Study description expanded, about 4 words
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Number of participants with treatment-related adverse events (AEs)
Timeframe: Part A: Up to 8 days; Part B: Up to 15 days; Part C: Up to 35 days;
Secondary (14)
Plasma pharmacokinetic (PK) parameter: Cmax
Plasma PK parameter: Tmax
Plasma PK parameter: AUClast
Plasma PK parameters: AUCinf
Plasma PK parameter: t1/2
Show 9 moreShow less
Plasma PK parameter: Apparent CL/F
Plasma PK parameter: Apparent Vd/F
Food effect on plasma PK: Cmax
Food effect on plasma PK: Tmax
Food effect on plasma PK: AUC
Urine PK parameter: CLr
Urine PK parameter: Cumulative amount excreted (urine)
Urine PK parameter: %Cumulative amount excreted
Feces PK parameter: Observed concentration
Arms and interventions
Part A SAD ActiveExperimental
Single Ascending Doses of VT-5006
Part A SAD PlaceboPlacebo comparator
Matched Placebo
Part B MAD ActiveExperimental
Multiple ascending doses of VT-5006
Part B MAD PlaceboPlacebo comparator
Matched Placebo
Part C Active Low DoseExperimental
Low dose VT-5006
Part C Active High DoseExperimental
High dose VT-5006
Part C PlaceboPlacebo comparator
Matched placebo
Drugs: VT-5006, Placebo
Sites
1 site in 1 country
- Center for Human Drug ResearchLeiden, Netherlands